This randomized comparison in India gave 150 chronic kidney disease patients either sevelamer carbonate or lanthanum carbonate (500 mg three times daily) and followed serum phosphate and routine blood tests for six months. Both binders lowered serum phosphate, and the lanthanum carbonate group showed the larger fall. Lanthanum itself was not measured in blood or tissue.
Key numbers
- Lanthanum carbonate dose: 500 mg three times daily with meals (n = 75) (Methods, p. 3; abstract).
- Serum phosphate in the lanthanum carbonate group fell from 8.79 plus or minus 2.11 to 4.02 plus or minus 1.30 mg/dL after six months (p. 5); the abstract reports the same means with different dispersion values.
Methods (brief)
Patients were divided equally between the two binders and assessed at enrollment, three months and six months for blood counts, liver and kidney function, electrolytes and serum phosphate. The abstract describes the study as running for one year while the follow-up reported covers six months.
Evidence fitness
Supports the statement that lanthanum carbonate is used as a long-term oral medicine in kidney disease, which is a distinct, high-dose exposure route. It provides no lanthanum concentrations, absorption or accumulation data.
Limitations
Small sample from limited sites (acknowledged by the authors); inconsistent dispersion values between abstract and text; no blinding described; no lanthanum measurement.
Related evidence
Update history
No substantive edit history is available in this build. The full commit record is available in git.